---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-028093"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:51:30.016825+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules

## Summary
- First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).
- Multicenter IRB-approved study will enroll up to 50 patients across four sites.
- Endpoints include safety, nodule volume reduction, symptom relief, quality of life, and cosmesis at 1, 3, 6, 12 months.
- CEO notes ongoing commercial launch pilot phase alongside clinical study progression.
- Principal investigator reports early positive results and organ-sparing potential.

## SEC filing metadata
- accession: 0001437749-25-028093
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/0001437749-25-028093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/plse20250829_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-028093
- JSON: https://secwatch.observer/filing/0001437749-25-028093.json
- Plain text: https://secwatch.observer/filing/0001437749-25-028093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.